UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF

REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES

EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-33882

 

 

Cascadian Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

3101 Western Avenue, Suite 600

Seattle, Washington 98121

(206) 801-2100

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   ☒

Rule 12g-4(a)(2)

   ☐

Rule 12h-3(b)(1)(i)

   ☒

Rule 12h-3(b)(1)(ii)

   ☐

Rule 15d-6

   ☐

Rule 15d-22(d)

   ☐

Approximate number of holders of record as of the certification or notice date: 1

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this certification/notice to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 22, 2018

 

Cascadian Therapeutics, Inc.
By:  

/s/ Venkat Ramanan

  Name:   Venkat Ramanan
  Title:   Vice President, Finance
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cascadian Therapeutics, Inc. Charts.
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cascadian Therapeutics, Inc. Charts.